Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Individuals eligible for enrollment in this study were female and male subjects who had shown to be healthy and who were:~1. Between 18 and 64 years of age inclusive and who had given their written informed consent;~2. Available for all visits and telephone calls scheduled for the study;~3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;~4. For female subjects, had a negative urine pregnancy test.~Exclusion Criteria:~Individuals not eligible to be enrolled in the study were those:~1. Who were breastfeeding.~2. Who had a previous personal history of Neisseria meningitidis, hepatitis A or hepatitis B infection.~3. Who received previous immunization with any meningococcal vaccine.~4. Who received previous hepatitis A and/or B vaccination, determined by history (interview of the subject) and/or by review of his or her vaccination card, if less than 5 years have elapsed since vaccination.~5. Who received investigational agents or vaccines within 30 days prior to enrollment or who expected to receive an investigational agent or vaccine prior to completion of the study.~6. Who received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine was anticipated during the study period (Exception: Influenza vaccine might have been administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization).~7. Who experienced, within the 7 days prior to enrollment, significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment.~8. Who had any serious acute, chronic or progressive disease such as:~   * History of cancer~  * Complicated diabetes mellitus~  * Advanced arteriosclerotic disease~  * Autoimmune disease~  * HIV infection or AIDS~  * Blood dyscrasias~  * Congestive heart failure~  * Renal failure~  * Severe malnutrition (Note: Subjects with mild asthma were eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids were not eligible for enrollment).~9. Who had epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome.~10. Who had a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including but not limited to latex allergy and antibiotic allergy.~11. Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):~    * Receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose \> 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);~   * Receipt of immunostimulants;~   * Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study.~12. Who were known to have a bleeding diathesis, or any condition that might have been associated with a prolonged bleeding time.~13. Who had any condition that, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.~14. Who were part of the study personnel or close family members of those conducting this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' alone on the different visits.
- Group 2 (Type: ACTIVE_COMPARATOR): This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
- Group 3 (Type: ACTIVE_COMPARATOR): This group will receive only MenACWY-CRM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete